--- title: "60 Degrees presents its July financing and cash runway to investors" url: "https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-08" section: "Financings" tickers: "NASDAQ:SXTP" source: "https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/ea030486201ex99-1.htm" summary: "A September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early" --- By the aibio.space news desk. Sources - [60 Degrees Pharmaceuticals, Inc. 8-K (2026-09-08)](https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/ea030486201ex99-1.htm) - [60 Degrees Pharmaceuticals, Inc. 10-K (2026-03-30): business](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/sxtp-20251231.htm) - [60 Degrees Pharmaceuticals, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) [SXTP](https://aibio.space/companies/60-degrees-pharmaceuticals/) 2026-09-08 # 60 Degrees presents its July financing and cash runway to investors Tickers [SXTP](https://aibio.space/companies/60-degrees-pharmaceuticals/) A September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026. ## Key facts - **Company**: 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) - **News type**: Financings - **Primary source**: [60 Degrees Pharmaceuticals, Inc. 8-K (2026-09-08)](https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/ea030486201ex99-1.htm) *A city skyline seen across a river. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.* 60 Degrees Pharmaceuticals, Inc. (NASDAQ: [SXTP](https://aibio.space/companies/60-degrees-pharmaceuticals/)) furnished an investor presentation dated September 8, 2026 as an exhibit to a Form 8-K. The deck was prepared for the H.C. Wainwright presentation. It sets out the company's capital structure after a July 2026 private placement and the Knight conversion, and it summarizes sales, cash use and the babesiosis development plan. ## The July financing The deck describes a July 31, 2026 private placement that raised $1.0M gross. Units were priced at $1.74 per share or per pre-funded warrant, with accompanying warrants. The placement included 191.6k common shares, 383.1k pre-funded warrants, and 574.7k Series A and 574.7k Series B warrants. The common warrant exercise price is $1.49. The deck also lists 43.1k placement-agent warrants at $2.175. The deck does not name the placement agent. It refers only to placement-agent warrants, and the filing sources for this story name no underwriter or placement agent by name. On a pro forma basis at July 31, 2026, the deck shows about 3.51M common shares outstanding. That total is the 2.659M base, plus 658.6k shares from the Knight conversion, plus the 191.6k common shares issued in the financing. It excludes pre-funded warrants. Preferred outstanding is 68,080 shares of Series A non-voting convertible preferred stock after the Knight conversion, with a 6% cumulative dividend. Common warrants total about 3.09M, including the July Series AB warrants and the placement-agent warrants. The deck says 383.1k pre-funded warrants were issued in the July 2026 private placement with a nominal $0.001 exercise price, and shows them separately from common. ## Cash and runway The deck reports about $1.0M of cash and equivalents at June 30, 2026, against about $5.0M of operating cash use over the six months ended June 30, 2026. It labels the runway as early October 2026. That date is weeks after the September 8 presentation, the deck names no further financing, and the July placement was priced with warrants that add to the share count. ## Sales of ARAKODA Second-quarter 2026 net product revenue for ARAKODA was $208k, up 106% from the year-earlier quarter. Gross profit on product revenue was $57k, a gross margin of about 27%. The deck says the commercial product now contributes a measurable revenue and gross profit line, while babesiosis development remains the main driver of capital needs. Product revenue of $208k is small against about $5.0M of cash used in six months. The quarterly report for the second quarter was filed August 14, 2026, and the deck cites it as the source for the second-quarter figures. ## The babesiosis case The deck says ticks are transmitting a widening set of serious diseases in the United States, with record tick-bite emergency room visits in 2026 of more than 113,000. It says babesiosis has at least 25k U.S. medical insurance claims a year and no FDA-approved treatment specifically for it. It puts the standard-of-care cure rate at 30% or less in relapsing immunosuppressed patients. The deck's investment focus is a marketed antimalarial platform that creates a path to potential indication expansion in babesiosis. It lists four milestones: the interim analysis, a pre-sNDA interaction with FDA, the sNDA filing, and a potential launch. The deck's forward-looking statements list, among other factors, substantial doubt about the company's ability to continue as a going concern. ## What comes next The deck's staged path runs through the interim analysis, the pre-sNDA interaction with FDA, the filing of a potential tafenoquine sNDA in babesiosis, and a potential launch. The deck gives no date for the sNDA filing beyond that sequence. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story SXTP 60 Degrees Pharmaceuticals, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "60 Degrees presents its July financing and cash runway to investors", 2026-09-08, https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/